Eileen O'Reilly, MD
There are several novel therapeutic approaches under investigation for the treatment of patients with pancreatic cancer. Immunotherapy, for example, has become an area of excitement, with early combination studies showing activity in these tumors.
on Gastrointestinal Cancers, Eileen O’Reilly, MD, associate director for Clinical Research, David M. Rubenstein Center for Pancreatic Cancer Research, Memorial Sloan Kettering Cancer Center, discussed novel therapeutic approaches for the treatment of patients with pancreatic cancer.
OncLive: Can you give an overview of your presentation on pancreatic cancer?
The initial part of my discussion was to review where we are with the current state-of-the-art frontline therapies for good performance status patients [treated] with FOLFIRINOX, gemcitabine, and nab-paclitaxel. There was a brief discussion of beyond frontline therapy with the relatively recent data of liposomal irinotecan [Onivyde] and fluorouracil.
The next part of the equation is understanding where the limits of DNA-repair inhibition are in pancreas cancer. Do genes beyond BRCA matter? Should we be looking for those and see what the impact of these types of therapies in those subpopulations are? It is a very interesting time in pancreas cancer. A lot is happening but there is more work to do and we remain hopeful.
What is the standard approach for sequencing?
We do not know how to fully apply this information but hopefully we will soon. It is going to be beyond single mutations. We will have the benefit of looking at multiple patients with different patterns and having annotated clinical outcomes that might say if a therapy is best applied to this person.
... to read the full story